JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meisetschläger, G.
Right arrow Articles by Schwaiger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meisetschläger, G.
Right arrow Articles by Schwaiger, M.

Gluc-Lys([18F]FP)-TOCA PET in Patients with SSTR-Positive Tumors: Biodistribution and Diagnostic Evaluation Compared with [111In]DTPA-Octreotide

Günther Meisetschläger, MD, Thorsten Poethko, PhD, Alexander Stahl, MD, Ingo Wolf, PhD, Klemens Scheidhauer, MD, Margret Schottelius, PhD, Michael Herz, PhD, Hans J. Wester, PhD and Markus Schwaiger, MD

Department of Nuclear Medicine, Technische Universität München, München, Germany


Figure 1
View larger version (12K):

[in a new window]
  		FIGURE 1.  Normalized serum time–activity curves of 10 patients expressed as percentage maximum divided by 100. Serum activity shows a biexponential elimination, with half-lives of t1/2(1) = 2.3 ± 1.3 min for the fast component and t1/2(2) = 26.4 ± 14.6 min for the slow component (error bars = 1 SD).

 

Figure 2
View larger version (12K):

[in a new window]
  		FIGURE 2.  Time–activity curve for kidney parenchyma and normal liver. Kidney activity shows initial rapid increase and continuous decrease until about 20 min after injection.

 

Figure 3
View larger version (21K):

[in a new window]
  		FIGURE 3.  Time course of SUVs in normal tissue (n = 8; error bars = 1 SD). Mean values of 8 patients are shown. Liver, lung, and muscle remain stable or decrease slightly over time; spleen shows mild increase over time. Increasing SUV in bile indicates hepatobiliary tracer excretion.

 

Figure 4
View larger version (20K):

[in a new window]
  		FIGURE 4.  Rapid development of high T/B ratios (t/b ratio) after sstr imaging using Gluc-Lys([18F]FP)-TOCA PET. Plot shows mean target-to-background ratios of 37 tumors located in liver (error bars = 1 SD). Eighty percent of the maximum value was reached within 16 ± 9 min and 90% of maximum T/B ratio was reached within 34 ± 12 min. Solid circles denote development of tumor SUV over time, which reaches a plateau at ~40 min. Solid triangles denote development of background SUV (liver) with mild decrease over time.

 

Figure 5
View larger version (109K):

[in a new window]
  		FIGURE 5.  Gluc-Lys([18F]FP)-TOCA PET and [111In]DTPA-octreotide scintigraphy in 50-y-old female patient with history of metastatic paraganglioma. In dorsal view of PET projection images (A), a large number of lesions can be delineated that are not visible in the posterior view of late [111In]DTPA-octreotide scintigraphy (B, 48 h after injection).

 

Figure 6
View larger version (53K):

[in a new window]
  		FIGURE 6.  Gluc-Lys([18F]FP)-TOCA PET and [111In]DTPA-octreotide SPECT (48 h after injection) in 53-y-old female patient with metastatic carcinoid of small intestine. Images are from caudal to cranial in 3 adjacent slices. Arrows indicate better delineation of 2 lesions on PET than on SPECT.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.